Botulinum Toxin Type A Composite Complex for Stability and Safety Margin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new botulinum toxin type A compositions that offer improved stability and safety compared to existing products like Botox®, which are limited in molecular weight and stability.
Innovation Solution
A Clostridium botulinum toxin Type A complex comprising HA70, HA17, HA33, NTNH, and BoNT/A1 components, with a molecular weight of 740-790 kDa, and a formulation including human serum albumin, methionine, arginine, sodium chloride, Polysorbate 80, citrate buffer, and phosphate buffer, enhancing stability and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional botulinum toxin type A products like Botox® are used, then therapeutic efficacy is achieved, but stability and safety margin are limited
Solution Approach 1:
The patent employs a composite protein complex structure comprising multiple subunits (HA70, HA33, HA17, NTNH, and BoNT/A1) that work synergistically to enhance both stability and safety. This composite approach allows the formulation to maintain therapeutic efficacy while improving resistance to degradation and increasing the safety margin compared to conventional single-component or simplified formulations.
2Ease of manufacture
If molecular weight is reduced to lower production cost, then manufacturing efficiency improves, but stability and safety may be compromised
Solution Approach 1:
The botulinum toxin type A complex is segmented into multiple functional subunits with specific molecular weights (HA70 at 70 kDa, HA33 at 33 kDa, HA17 at 17 kDa, NTNH at 138 kDa, and BoNT/A1 at 149 kDa). This segmentation allows for optimized production of individual components that can be assembled into a stable complex, achieving a balance between manufacturing efficiency and safety through modular construction rather than requiring a single large protein molecule.
Data Source
AI summary
The present invention relates to a botulinum toxin type A complex, and a formulation thereof and a usage method therefor. The present invention provides the botulinum toxin type A complex, comprising an HA70 component, and an HA17 component, an HA33 component, an NINH component, and a BoNT/A1 component, wherein the botulinum toxin complex has a molecular weight of 740-790 kDa. Compared with the existing botulinum toxin complexes, the botulinum toxin complex of the present invention is smaller in molecular weight and higher in safety, and has a comparable treatment effect.